Benefit-Risk Tradeoffs in Assessment of New Drugs and Devices.

Circulation
Sanjay KaulJaved Butler

Abstract

Balancing benefits and risks is a complex task that poses a major challenge, both to the approval of new medicines and devices by regulatory authorities and in therapeutic decision-making in practice. Several analysis methods and visualization tools have been developed to help evaluate and communicate whether the benefit-risk profile is favorable or unfavorable. In this White Paper, we describe approaches to benefit-risk assessment using qualitative approaches such as the Benefit Risk Action Team framework developed by the Pharmaceutical Research and Manufacturers of America, and the Benefit-Risk Framework developed by the United States Food and Drug Administration; and quantitative approaches such as the numbers needed to treat for benefit and harm, the benefit-risk ratio, and Incremental Net Benefit. We give illustrative examples of benefit-risk evaluations using 4 treatment interventions including sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes; a direct antithrombin agent, dabigatran, for reducing stroke and systemic embolism in patients with nonvalvular atrial fibrillation; transcatheter aortic valve replacement in patients with symptomatic severe aortic valve stenosis; and antiplatelet agents vo...Continue Reading

References

Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Sep 4, 2009·The New England Journal of Medicine·Ellis F Unger
Feb 2, 2010·Journal of the American College of Cardiology·Sanjay Kaul, George A Diamond
Apr 24, 2010·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Jeff J GuoDennis W Raisch
Oct 22, 2010·The New England Journal of Medicine·Martin B LeonUNKNOWN PARTNER Trial Investigators
Apr 15, 2011·The New England Journal of Medicine·B Nhi BeasleyRobert Temple
Jun 7, 2011·The New England Journal of Medicine·Craig R SmithUNKNOWN PARTNER Trial Investigators
Mar 27, 2012·The New England Journal of Medicine·David A MorrowUNKNOWN TRA 2P–TIMI 50 Steering Committee and Investigators
Aug 28, 2012·The New England Journal of Medicine·Matthew T RoeUNKNOWN TRILOGY ACS Investigators
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Sep 14, 2017·The New England Journal of Medicine·Satish K GargPaul Strumph
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators
Feb 8, 2019·JAMA : the Journal of the American Medical Association·Jeffrey L Saver, Roger J Lewis
Apr 17, 2019·The New England Journal of Medicine·Vlado PerkovicUNKNOWN CREDENCE Trial Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Related Papers

American Journal of Pharmacy and the Sciences Supporting Public Health
L F Tice
Journal of the American College of Cardiology
P R KoweyR A Marinchak
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association
J M LuteijnH Verhagen
© 2021 Meta ULC. All rights reserved